|
1
|
The ethics statement of the Vancouver Forum on the live lung, liver, pancreas, and intestine donor.
|
Transplantation
|
2006
|
3.24
|
|
2
|
Excerpts from the United States Renal Data System 2004 annual data report: atlas of end-stage renal disease in the United States.
|
Am J Kidney Dis
|
2005
|
2.81
|
|
3
|
National conference to assess antibody-mediated rejection in solid organ transplantation.
|
Am J Transplant
|
2004
|
2.01
|
|
4
|
Angiotensin II blockade in kidney transplant recipients.
|
J Am Soc Nephrol
|
2013
|
1.77
|
|
5
|
Excerpts from the United States Renal Data System 2003 Annual Data Report: atlas of end-stage renal disease in the United States.
|
Am J Kidney Dis
|
2003
|
1.70
|
|
6
|
A molecular classifier for predicting future graft loss in late kidney transplant biopsies.
|
J Clin Invest
|
2010
|
1.61
|
|
7
|
Promotion of altruistic donation: a reply.
|
Transplantation
|
2010
|
1.40
|
|
8
|
GFR-estimating models in kidney transplant recipients on a steroid-free regimen.
|
Nephrol Dial Transplant
|
2010
|
1.04
|
|
9
|
Two years postconversion from a prograf-based regimen to a once-daily tacrolimus extended-release formulation in stable kidney transplant recipients.
|
Transplantation
|
2007
|
1.01
|
|
10
|
Graft loss from recurrent glomerulonephritis is not increased with a rapid steroid discontinuation protocol.
|
Transplantation
|
2006
|
0.95
|
|
11
|
Thymoglobulin versus ATGAM induction therapy in pediatric kidney transplant recipients: a single-center report.
|
Transplantation
|
2005
|
0.93
|
|
12
|
Pediatric kidney transplantation using a novel protocol of rapid (6-day) discontinuation of prednisone: 2-year results.
|
Transplantation
|
2009
|
0.91
|
|
13
|
Pretransplant donor-specific and non-specific immune parameters associated with early acute rejection.
|
Transplantation
|
2008
|
0.91
|
|
14
|
Pharmacogenetic effect of the UGT polymorphisms on mycophenolate is modified by calcineurin inhibitors.
|
Eur J Clin Pharmacol
|
2008
|
0.88
|
|
15
|
Surrogate markers for long-term renal allograft survival.
|
Am J Transplant
|
2004
|
0.85
|
|
16
|
Incentives for organ donation in the United States: feasible alternative or forthcoming apocalypse?
|
Curr Opin Organ Transplant
|
2009
|
0.83
|
|
17
|
Transplant tourism and unregulated black-market trafficking of organs.
|
Am J Transplant
|
2009
|
0.80
|
|
18
|
The impact of C4d and microvascular inflammation before we knew them.
|
Clin Transplant
|
2013
|
0.79
|
|
19
|
Perioperative outcomes of cardiac surgery in kidney and kidney-pancreas transplant recipients.
|
J Thorac Cardiovasc Surg
|
2007
|
0.77
|
|
20
|
Improved late graft survival and half-lives in pediatric kidney transplantation: a single center experience.
|
Am J Transplant
|
2002
|
0.76
|
|
21
|
Squamous cell carcinoma of the head and neck in solid organ transplant recipients.
|
Head Neck
|
2002
|
0.76
|
|
22
|
High immunologic risk living donor kidney transplant using bortezomib in a novel induction regimen without acute antibody mediated rejection.
|
Clin Transpl
|
2011
|
0.75
|
|
23
|
Human leukocyte antigen type as a risk factor for nonmelanomatous skin cancer in patients after renal transplantation.
|
Transplantation
|
2004
|
0.75
|
|
24
|
Selection of controls in kidney donor outcome studies: an admirable effort.
|
Am J Kidney Dis
|
2012
|
0.75
|
|
25
|
The point of control: Can a regulated organ market be moral?
|
Hastings Cent Rep
|
2009
|
0.75
|
|
26
|
Rapid Discontinuation of Prednisone in Kidney Transplant Recipients: 15-Year Outcomes from the University of Minnesota.
|
Transplantation
|
2017
|
0.75
|